Ms Evelyn Glennys Villar, ARNP | |
360 Douglas Ave, Altamonte Springs, FL 32714-3335 | |
(407) 788-8200 | |
(407) 788-3746 |
Full Name | Ms Evelyn Glennys Villar |
---|---|
Gender | Female |
Speciality | Nurse Practitioner - Family |
Location | 360 Douglas Ave, Altamonte Springs, Florida |
Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
Identifier | Type | State | Issuer |
---|---|---|---|
1164754925 | NPI | - | NPPES |
002942600 | Medicaid | FL |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
208100000X | Physical Medicine & Rehabilitation | ARNP9259806 (Florida) | Secondary |
363LF0000X | Nurse Practitioner - Family | ARNP9259806 (Florida) | Primary |
Entity Name | Centerwell Senior Primary Care Fl Inc. |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1487686705 PECOS PAC ID: 9830184738 Enrollment ID: O20040419001657 |
News Archive
The country's first not-for-profit independent medical school, at The University of Buckingham, has received GMC accreditation and will graduate its first cohort of students on 29 June.
"Drought in some areas and heavy rain in others are keeping world food prices near record levels, threatening the food supply for poorer, food-importing countries," the U.N. Food and Agriculture Organization (FAO) said in its biannual report on Tuesday, the Wall Street Journal reports.
For years, doctors have warned patients to finish their antibiotic prescriptions or risk a renewed infection by a "superbug" that can mount a more powerful defense against the same drug. But a new study by Boston University biomedical engineers indicates that treating bacteria with levels of antibiotics insufficient to kill them produces germs that are cross-resistant to a wide range of antibiotics.
Simple remedies - from keeping the antibacterial gel dispenser clean to giving health care workers their own hand sanitizer - can help keep patients safe by decreasing contamination in operating and recovery rooms, suggest two studies presented at the ANESTHESIOLOGY 2013 annual meeting.
Specialty biopharmaceutical company Santarus, Inc. and biotech company Pharming Group NV today announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) to obtain marketing approval for RHUCIN® (recombinant human C1 inhibitor) for the treatment of acute angioedema attacks in patients with Hereditary Angioedema (HAE).
› Verified 4 days ago
Mailing Address | Practice Location Address |
---|---|
Ms Evelyn Glennys Villar, ARNP 4700 Millenia Blvd Ste 650, Orlando, FL 32839-6013 Ph: (407) 447-7120 | Ms Evelyn Glennys Villar, ARNP 360 Douglas Ave, Altamonte Springs, FL 32714-3335 Ph: (407) 788-8200 |
News Archive
The country's first not-for-profit independent medical school, at The University of Buckingham, has received GMC accreditation and will graduate its first cohort of students on 29 June.
"Drought in some areas and heavy rain in others are keeping world food prices near record levels, threatening the food supply for poorer, food-importing countries," the U.N. Food and Agriculture Organization (FAO) said in its biannual report on Tuesday, the Wall Street Journal reports.
For years, doctors have warned patients to finish their antibiotic prescriptions or risk a renewed infection by a "superbug" that can mount a more powerful defense against the same drug. But a new study by Boston University biomedical engineers indicates that treating bacteria with levels of antibiotics insufficient to kill them produces germs that are cross-resistant to a wide range of antibiotics.
Simple remedies - from keeping the antibacterial gel dispenser clean to giving health care workers their own hand sanitizer - can help keep patients safe by decreasing contamination in operating and recovery rooms, suggest two studies presented at the ANESTHESIOLOGY 2013 annual meeting.
Specialty biopharmaceutical company Santarus, Inc. and biotech company Pharming Group NV today announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) to obtain marketing approval for RHUCIN® (recombinant human C1 inhibitor) for the treatment of acute angioedema attacks in patients with Hereditary Angioedema (HAE).
› Verified 4 days ago